Interleukin 8, Recombinant, Human (IL-8)

Source: \nRecombinant corresponding to 72aa from human Interleukin 8 expressed in E. coli.\n\nMolecular Weight: \n~8kD\n\nEndotoxin: (same/less than)0.1ng/ug\n\nActivity:\nED50 range =20-100 ng/ml, determined by human neutrophil chemotaxis in a modified Boyden chamber. Optimal concentration for individual application should be determined by a dose response assay.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I8430-10B

Size

25ug

Form

Supplied as a lyophilized powder. BSA free. Reconstitute with sterile ddH2O to 0.1-1mg/ml.

Purity

~95% (SDS-PAGE)

References

1. Clark-Lewis, I., et al. (1991) Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. J. Biol. Chem. 266(34):23128-34. 2. Esser, M. T., D.M. Haverstick, C.L. Fuller, C.A. Gullo, and V.L. Braciale (1998) Ca2+ signaling modulates cytolytic T lymphocyte effector functions. J. Exp. Med. 187(7):1057-67. 3. Graham, M.B. and T.J. Braciale (1997) Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J. Exp. Med. 186(12):2063-8. 4. Rajan, R., R. Vanderslice, S. Kapur, J. Lynch, R. Thompson, and D. Djakiew (1996) Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 28(1):1-9. 5. Wagers, A.J., C.M. Waters, L.M. Stoolman, and G.S. Kansas (1998) Interleukin 12 and interleukin 4 control T cell adhesion to endothelial selectins through opposite effects on alpha1, 3-fucosyltransferase VII gene expression. J. Exp. Med. 188(12):2225-31. 6. Weng, Y., S.J. Siciliano, K.E. Waldburger, A. Sirotina-Meisher, M.J. Staruch, B.L. Daugherty, S.L. Gould, M.S. Springer, and J.A. DeMartiono (1998) Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J. Biol. Chem. 273(29):18288-91. 7. Loparev, V., J. Parsons, J. Knight, J. Fanelli Panus, C. Ray, R. Buller, D. Pickup, and J. Esposito (1998) A third distinct tumor necrosis factor receptor of orthopoxviruses. Proc. Nat